Genovis AB Stock Nasdaq Stockholm
Equities
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
||
- SEK | - |
May. 15 | Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 14 | Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement | CI |
Sales 2024 * | 154M 14.77M | Sales 2025 * | 189M 18.21M | Capitalization | 2.39B 230M |
---|---|---|---|---|---|
Net income 2024 * | 40M 3.85M | Net income 2025 * | 49M 4.71M | EV / Sales 2024 * | 14.8 x |
Net cash position 2024 * | 108M 10.42M | Net cash position 2025 * | 128M 12.3M | EV / Sales 2025 * | 11.9 x |
P/E ratio 2024 * |
58.9
x | P/E ratio 2025 * |
49.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Managers | Title | Age | Since |
---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 01-12-31 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 21-12-31 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 72 | 20-05-04 | |
Director/Board Member | 63 | 18-12-31 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 13-12-31 |
1st Jan change | Capi. | |
---|---|---|
-5.12% | 8.16B | |
+8.00% | 5.82B | |
+31.68% | 5.72B | |
-12.56% | 4.01B | |
+12.16% | 2.75B | |
-59.86% | 2.66B | |
-5.70% | 2.39B | |
+17.79% | 2.05B | |
-7.86% | 1.82B |